チアゾリジンジオン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "チアゾリジンジオン" in Japanese language version.

refsWebsite

Global rank Japanese rank

19nih.gov

4^th place

24^th place

10doi.org

2^nd place

6^th place

3web.archive.org

1^st place

2clinicaltrials.gov

5,225^th place

low place

1nhs.uk

1,989^th place

4,341^st place

1huliq.com

low place

1jneuroinflammation.com

low place

1forbes.com

54^th place

269^th place

1diabetesjournals.org

low place

1ama-assn.org

3,257^th place

6,629^th place

1fda.gov

447^th place

1,043^rd place

1springer.com

274^th place

596^th place

ama-assn.org

jama.ama-assn.org

Nissen SE, Nicholls SJ, Wolski K, et al. (April 2008). “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial”. JAMA 299 (13): 1561–73. doi:10.1001/jama.299.13.1561. PMID 18378631.

clinicaltrials.gov

Belfort R, Harrison SA, Brown K, et al. (November 2006). “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis”. N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584. Clinical trial info
Clinical Trials for Rosiglitazone - from ClinicalTrials.gov, a service of the U.S. National Institutes of Health

diabetesjournals.org

care.diabetesjournals.org

Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A (July 2004). “The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients”. Diabetes Care 27 (7): 1647–53. doi:10.2337/diacare.27.7.1647. PMID 15220241.

doi.org

Panigrahy D, Singer S, Shen LQ, et al. (2002). “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis”. J. Clin. Invest. 110 (7): 923–32. doi:10.1172/JCI15634. PMC 151148. PMID 12370270.
Belfort R, Harrison SA, Brown K, et al. (November 2006). “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis”. N. Engl. J. Med. 355 (22): 2297–307. doi:10.1056/NEJMoa060326. PMID 17135584. Clinical trial info
Krentz AJ, Friedmann PS (March 2006). “Type 2 diabetes, psoriasis and thiazolidinediones”. Int. J. Clin. Pract. 60 (3): 362–3. doi:10.1111/j.1368-5031.2005.00765.x. PMID 16494655.
Shah DK, Menon KM, Cabrera LM, Vahratian A, Kavoussi SK, Lebovic DI (April 2010). “Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro”. Fertil. Steril. 93 (6): 2042–7. doi:10.1016/j.fertnstert.2009.02.059. PMC 2847675. PMID 19342033.
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A (July 2004). “The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients”. Diabetes Care 27 (7): 1647–53. doi:10.2337/diacare.27.7.1647. PMID 15220241.
Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N (May 2008). “Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials”. Diabetes Obes Metab 0 (12): 1221–38. doi:10.1111/j.1463-1326.2008.00892.x. PMID 18505403.
Nissen SE, Nicholls SJ, Wolski K, et al. (April 2008). “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial”. JAMA 299 (13): 1561–73. doi:10.1001/jama.299.13.1561. PMID 18378631.
Blind E, Dunder K, de Graeff PA, Abadie E (2011). “Rosiglitazone: a European regulatory perspective”. Diabetologia 54 (2): 213–8. doi:10.1007/s00125-010-1992-5. PMID 21153629. オリジナルの2014年3月30日時点におけるアーカイブ。.
Kendall C, Wooltorton E (2006). “Rosiglitazone (Avandia) and macular edema”. CMAJ 174 (5): 623. doi:10.1503/cmaj.060074. PMC 1389823. PMID 16467508.
Loke, Y. K.; Singh, S.; Furberg, C. D. (6 January 2009). “Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis”. Canadian Medical Association Journal 180 (1): 32–39. doi:10.1503/cmaj.080486.

fda.gov

“アーカイブされたコピー”. 2015年5月4日時点のオリジナルよりアーカイブ。2015年4月23日閲覧。

forbes.com

“Avandia to Carry Stronger Heart Failure Warning - Forbes.com”. 2007年10月21日時点のオリジナルよりアーカイブ。2007年8月15日閲覧。

huliq.com

Diabetes Drug Actos Sales Suspended in France and Germany | HULIQ

jneuroinflammation.com

Boris et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children, Journal of Neuroinflammation 2007,4:3 [1]

nhs.uk

NHS: Avandia diabetes drug suspended, Friday 24 September 2010

nih.gov

springer.com

download.springer.com

Blind E, Dunder K, de Graeff PA, Abadie E (2011). “Rosiglitazone: a European regulatory perspective”. Diabetologia 54 (2): 213–8. doi:10.1007/s00125-010-1992-5. PMID 21153629. オリジナルの2014年3月30日時点におけるアーカイブ。.

web.archive.org

“Avandia to Carry Stronger Heart Failure Warning - Forbes.com”. 2007年10月21日時点のオリジナルよりアーカイブ。2007年8月15日閲覧。
“アーカイブされたコピー”. 2015年5月4日時点のオリジナルよりアーカイブ。2015年4月23日閲覧。
Blind E, Dunder K, de Graeff PA, Abadie E (2011). “Rosiglitazone: a European regulatory perspective”. Diabetologia 54 (2): 213–8. doi:10.1007/s00125-010-1992-5. PMID 21153629. オリジナルの2014年3月30日時点におけるアーカイブ。.

チアゾリジンジオン (Japanese Wikipedia)

ama-assn.org

jama.ama-assn.org

clinicaltrials.gov

diabetesjournals.org

care.diabetesjournals.org

doi.org

fda.gov

forbes.com

huliq.com

jneuroinflammation.com

nhs.uk

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov

springer.com

download.springer.com

web.archive.org